NVCT

Dopo l'orario di chiusura: 6.38 -0.02 -0.31%

Nuvectis Pharma Inc (NVCT)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Nuvectis Pharma Inc

360-837-7232

1 BRIDGE PLAZA, SUITE 275, FORT LEE

Prossima data di guadagno

Ultimi documenti SEC

NVCT's Discussions on Twitter

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-07-13	Iniziato	Ladenburg Thalmann	Buy

Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie

Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari

Nuvectis Pharma Inc Azioni (NVCT) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
BENTSUR RON	Chairman & CEO	May 10 '24	Buy	6.40	2,000	12,800	3,244,484
Poradosu Enrique	Chief Science & Business Off	May 10 '24	Buy	6.29	500	3,145	1,504,319
Shemesh Shay	Chief Dev. & Ops. Officer	May 10 '24	Buy	6.32	1,113	7,034	1,493,068
BENTSUR RON	Chairman & CEO	Mar 18 '24	Buy	10.29	5,000	51,450	3,242,484
BENTSUR RON	Chairman & CEO	Oct 10 '23	Buy	11.08	640	7,091	3,237,484
BENTSUR RON	Chairman & CEO	Oct 09 '23	Buy	11.19	830	9,288	3,236,844
BENTSUR RON	Chairman & CEO	Oct 06 '23	Buy	11.27	250	2,818	3,236,014
BENTSUR RON	Chairman & CEO	Oct 04 '23	Buy	10.95	1,820	19,929	3,234,364
BENTSUR RON	Chairman & CEO	Oct 05 '23	Buy	11.09	1,400	15,526	3,235,764

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch - StockTitan

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 8.5% - MarketBeat

Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5% - Defense World

Nuvectis’ NXP800 gains FDA ODD for cancer treatment - MSN

Insider Buyers Lose Additional US$46k As Nuvectis Pharma Dips To US$115m - Simply Wall St

When (NVCT) Moves Investors should Listen - Stock Traders Daily

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Nuvectis Pharma Inc (NVCT) Becoming More Attractive for Investors - Knox Daily

Is Nuvectis Pharma Inc (NVCT) worth investing in despite its overvalued state? - US Post News

The time has not yet come to remove your chips from the table: Nuvectis Pharma Inc (NVCT) - SETE News

Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 - World Pharmaceutical Frontiers

Nuvectis’ NXP800 gains FDA ODD for cancer treatment - Yahoo Finance

Nuvectis’ NXP800 gains FDA ODD for cancer treatment - Pharmaceutical Technology

Nuvectis Pharma receives FDA orphan drug status for cancer treatment - Investing.com India

Nuvectis Pharma Announces Orphan Drug Designation Granted - GlobeNewswire

Nuvectis Pharma Secures FDA Orphan Drug Designation for NXP800, Advancing Treatment for Rare Ovarian Cancers - Vancity Buzz

Precision Medicine Trailblazer Nuvectis Pharma Secures FDA Orphan Drug Designation for NXP800 - Markets Herald

Nuvectis stock gains on FDA’s orphan status (NASDAQ:NVCT) - Seeking Alpha

Nuvectis Shares Rally After Ovarian Cancer Drug Gets FDA's Orphan Drug Designation - MarketWatch

Nuvectis Pharma receives FDA orphan drug status for cancer treatment - Investing.com

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers - StockTitan

Positive Signs As Multiple Insiders Buy Nuvectis Pharma Stock - Yahoo Finance

Recent Insider Activity Could Benefit Nuvectis Pharma Inc (NVCT) - Knox Daily

Vanguard Group Inc. Has $2.45 Million Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

How the (NVCT) price action is used to our Advantage - Stock Traders Daily

Approaching Potentially Game-Changing Clinical Data: - openPR

Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) - Barchart

Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) | FinancialContent Business Page - Financial Content

Nuvectis Pharma, Inc. to Post Q3 2024 Earnings of ($0.26) Per Share, HC Wainwright Forecasts (NASDAQ:NVCT) - MarketBeat

Q3 2024 EPS Estimates for Nuvectis Pharma, Inc. Increased by HC Wainwright (NASDAQ:NVCT) - Defense World

Nuvectis Pharma, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.25) Per Share (NASDAQ:NVCT) - Defense World

Nuvectis Pharma’s (NVCT) Buy Rating Reaffirmed at HC Wainwright - Defense World

Nuvectis Pharma (NASDAQ:NVCT) Rating Reiterated by HC Wainwright - MarketBeat

Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - StockTitan

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - Yahoo Finance

Recent 11% decline may not have gone down well with Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who've been purchasing recently - Simply Wall St

(NVCT) Investment Analysis - Stock Traders Daily

5 Reasons Why Nuvectis Pharma (NASDAQ: NVCT) Is a Biopharma Innovator to Watch - Market Research Record

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest Down 18.1% in July - MarketBeat

Insiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently - Yahoo Finance

Long Term Trading Analysis for (NVCT) - Stock Traders Daily

Reviewing Nuvectis Pharma (NASDAQ:NVCT) and NanoViricides (NYSE:NNVC) - Defense World

Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market - openPR

Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market - The Globe and Mail

Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market - Barchart

Market Momentum Report: Nuvectis Pharma Inc (NVCT)'s Negative Close at 6.20 – DWinneX - The Dwinnex

NVCT Stock Sees Decline of Approximately -4.62% in Last Five Days – Knox Daily - Knox Daily

Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Nuvectis Pharma Inc Azioni (NVCT) insider trading

Simile a NVCT